Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from Lonza Group Ltd ( (CH:LONN) ).
Lonza reported first-half 2026 sales of CHF 3.4 billion, with constant currency growth of 16.0% and a core EBITDA margin rising to 34.8%, driven by strong demand, operational leverage and favorable product mix. Free cash flow improved to CHF 0.4 billion as capital expenditure normalized, and all business platforms delivered double-digit sales growth, underscoring the resilience of its CDMO-focused model.
The group advanced its One-Lonza strategy by agreeing to sell its Capsules & Health Ingredients business and committing to return CHF 500 million to shareholders via a share buyback, while reinvesting remaining proceeds to fund organic projects and M&A. It also announced further ADC-related capacity expansions in Visp and Stein and raised its full-year 2026 core EBITDA margin outlook to 33–34%, signalling stronger profitability and reinforced positioning in high-growth outsourced biopharma manufacturing.
The most recent analyst rating on (CH:LONN) stock is a Buy
with a CHF650.00 price target.
To see the full list of analyst forecasts on Lonza Group Ltd stock,
see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza Group AG is a Switzerland-based contract development and manufacturing organization serving global pharma and biotech companies with biologics, small molecules and advanced therapies. The company focuses on strategic outsourcing, offering integrated end-to-end services including mammalian manufacturing, bioconjugates, microbial production and drug product capabilities to support clinical and commercial supply.
Average Trading Volume: 162,697
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF38.5B
Learn more about LONN stock on TipRanks’ Stock Analysis page.